UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease

Clinical and experimental allergy, 2021-08, Vol.51 (8), p.1046-1056

2021

Volltextzugriff (PDF)

Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps

Diagnostics (Basel), 2021-01, Vol.11 (1), p.135

2021

Volltextzugriff (PDF)

The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria – a pilot study

Postȩpy dermatologii i alergologii, 2020-01, Vol.37 (1), p.73-80

2020

Volltextzugriff (PDF)

Bullous skin lesion reaction as an example of an adverse effect of a preparation containing 0.1% octenidine dihydrochloride and 2% phenoxyethanol (Octenisept®)

Przegląd dermatologiczny, 2018-01, Vol.105 (6), p.753-760

2018

Volltextzugriff (PDF)

The prevalence of asthma work relatedness: Preliminary data

International journal of occupational medicine and environmental health, 2015-01, Vol.28 (6), p.1025-1029

2015

Volltextzugriff (PDF)

Sputum biomarkers during aspirin desensitization in nonsteroidal anti-inflammatory drugs exacerbated respiratory disease

Respiratory medicine, 2019-06, Vol.152, p.51-59

2019

Volltextzugriff (PDF)

Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-12, Vol.9 (12), p.4431-4440.e1

2021

Volltextzugriff (PDF)

Expression of cPLA2γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen

International journal of immunopathology and pharmacology, 2021, Vol.35, p.2058738421990952-2058738421990952

2021

Volltextzugriff (PDF)

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-09, Vol.10 (9), p.2367-2374.e3

2022

Volltextzugriff (PDF)

POLASTMA--the Polish National Programme of Early Diagnosis and Therapy of Asthma

Advances in respiratory medicine, 2014, Vol.82 (6), p.597-607

2014

Volltextzugriff (PDF)

Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study

American journal of respiratory and critical care medicine, 2021-04, Vol.203 (7), p.871-881

2021

Volltextzugriff (PDF)

The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab

Advances in respiratory medicine, 2015, Vol.83 (4), p.335-338

2015

Volltextzugriff (PDF)

Artificial neural network identifies nonsteroidal anti‐inflammatory drugs exacerbated respiratory disease (N‐ERD) cohort

Allergy (Copenhagen), 2020-07, Vol.75 (7), p.1649-1658

2020

Volltextzugriff (PDF)

New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?

Clinical and translational allergy, 2020-06, Vol.10 (1), p.1-n/a, Article 19

2020

Volltextzugriff (PDF)

The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma

Advances in respiratory medicine, 2016, Vol.84 (4), p.232-243

2016

Volltextzugriff (PDF)

The Step Further to Understand the Role of Cytosolic Phospholipase A2 Alpha and Group X Secretory Phospholipase A2 in Allergic Inflammation: Pilot Study

BioMed research international, 2014, Vol.2014 (2014), p.1-9

2014

Volltextzugriff (PDF)

Expression of cPLA 2 γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen

International journal of immunopathology and pharmacology, 2021-01, Vol.35, p.2058738421990952

2021

Volltextzugriff (PDF)

Relapse Of Severe Asthma Exacerbations After Cessation Of Omalizumab Treatment – Real Life Data

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB1-AB1

2014

Volltextzugriff (PDF)

Exacerbating Factors Induce Different Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Asthmatics, Patients with Chronic Obstructive Pulmonary Disease and Healthy Subjects

International archives of allergy and immunology, 2014-01, Vol.165 (4), p.229-243

2014

Volltextzugriff (PDF)

Omalizumab Therapy in Patient Suffering from Severe Asthma and Concomitant Ulcerative Colitis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB1-AB1

2015

Volltextzugriff (PDF)

Comparison of Omalizumab Therapy Effectiveness in Patients with Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) and Patients Who Tolerate NSAID (non-NSAID) – Polish Real Life Experience

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB390-AB390

2016

Volltextzugriff (PDF)

Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle formulation in a real-life setting in Poland: the CASPER noninterventional, observational trial

Polskie archiwum medycyny wewne̦trznej, 2015-01, Vol.125 (10), p.731-740

2015

Volltextzugriff (PDF)

Zmiany najnowszych Wytycznych Leczenia i Prewencji Astmy—GINA 2014. Na co powinniśmy zwrócić uwagę?

Advances in respiratory medicine, 2014-08, Vol.82 (5), p.393-401

2014

Volltextzugriff (PDF)

Predictors of excessive short-acting b2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database

Postȩpy dermatologii i alergologii, 2023, Vol.40 (6), p.790-797

2023

Volltextzugriff (PDF)

Wpływ omalizumabu na zapalenie eozynofilowe dróg oddechowych u pacjentów chorych na astmę alergiczną

Advances in respiratory medicine, 2016-08, Vol.84 (105), p.15-26

2016

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(78)

Sprache

Englisch
(66)
Polnisch
(14)

Erscheinungsjahr

n.n

Thema

Humans
(31)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Asthma
(25)
Female
(23)
Male
(23)
Adult
(20)
Middle Aged
(18)
Allergy
(16)
Aged
(10)
Asthma - Drug Therapy
(10)
Adolescent
(9)
Dermatology
(9)
Immunology
(7)
Omalizumab
(7)
Patients
(7)
Treatment Outcome
(7)
Anti-Asthmatic Agents - Therapeutic Use
(6)
Aspirin
(6)
Drug Dosages
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease

Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps

The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria – a pilot study

Bullous skin lesion reaction as an example of an adverse effect of a preparation containing 0.1% octenidine dihydrochloride and 2% phenoxyethanol (Octenisept®)

The prevalence of asthma work relatedness: Preliminary data

Sputum biomarkers during aspirin desensitization in nonsteroidal anti-inflammatory drugs exacerbated respiratory disease

Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study

Expression of cPLA2γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

POLASTMA--the Polish National Programme of Early Diagnosis and Therapy of Asthma

Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study

The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab

Artificial neural network identifies nonsteroidal anti‐inflammatory drugs exacerbated respiratory disease (N‐ERD) cohort

New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?

The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma

The Step Further to Understand the Role of Cytosolic Phospholipase A2 Alpha and Group X Secretory Phospholipase A2 in Allergic Inflammation: Pilot Study

Expression of cPLA 2 γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen

Relapse Of Severe Asthma Exacerbations After Cessation Of Omalizumab Treatment – Real Life Data

Exacerbating Factors Induce Different Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Asthmatics, Patients with Chronic Obstructive Pulmonary Disease and Healthy Subjects

Omalizumab Therapy in Patient Suffering from Severe Asthma and Concomitant Ulcerative Colitis

Comparison of Omalizumab Therapy Effectiveness in Patients with Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) and Patients Who Tolerate NSAID (non-NSAID) – Polish Real Life Experience

Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle formulation in a real-life setting in Poland: the CASPER noninterventional, observational trial

Zmiany najnowszych Wytycznych Leczenia i Prewencji Astmy—GINA 2014. Na co powinniśmy zwrócić uwagę?

Predictors of excessive short-acting b2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database

Wpływ omalizumabu na zapalenie eozynofilowe dróg oddechowych u pacjentów chorych na astmę alergiczną

Suchergebnisse filtern